An anti-CTLA-4 heavy chain–only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile

The value of anti-CTLA-4 antibodies in cancer therapy is well established. However, the broad application of currently available anti-CTLA-4 therapeutic antibodies is hampered by their narrow therapeutic index. It is therefore challenging and attractive to develop the next generation of anti-CTLA-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Xin, Shan, Qianqian, Li, He, Janssens, Rick, Shen, Yuqiang, He, Yun, Chen, Fei, van Haperen, Rien, Drabek, Dubravka, Li, Jin, Zhang, Yang, Zhao, Jiuqiao, Qin, Beibei, Jheng, Ming-Jin, Chen, Victor, Wang, Jingsong, Rong, Yiping, Grosveld, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371702/
https://www.ncbi.nlm.nih.gov/pubmed/35925889
http://dx.doi.org/10.1073/pnas.2200879119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371702/
https://www.ncbi.nlm.nih.gov/pubmed/35925889
http://dx.doi.org/10.1073/pnas.2200879119

Ejemplares similares